[go: up one dir, main page]

AR029139A1 - Interleuquina 2 estabilizada - Google Patents

Interleuquina 2 estabilizada

Info

Publication number
AR029139A1
AR029139A1 ARP010102841A ARP010102841A AR029139A1 AR 029139 A1 AR029139 A1 AR 029139A1 AR P010102841 A ARP010102841 A AR P010102841A AR P010102841 A ARP010102841 A AR P010102841A AR 029139 A1 AR029139 A1 AR 029139A1
Authority
AR
Argentina
Prior art keywords
interleuquina
stabilized
variant
preferred formulation
reconstitution
Prior art date
Application number
ARP010102841A
Other languages
English (en)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24424265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR029139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR029139A1 publication Critical patent/AR029139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)

Abstract

Una preparacion farmacéutica estable que comprende interleuquina-2 Humana o una variante de la misma y una cantidad estabilizante de histidina. Una formulacion preferida incluye glicina y sacarosa y una variante de II-2 que tiene una mutacion simple, N88R. La formulacion preferida es una forma liofilizada, que con la reconstitucion con un diluyente acuoso, produce una solucion que tiene un pH que varía desde aproximadamente 5,0 a 6,5.
ARP010102841A 2000-06-28 2001-06-14 Interleuquina 2 estabilizada AR029139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/605,577 US6689353B1 (en) 2000-06-28 2000-06-28 Stabilized interleukin 2

Publications (1)

Publication Number Publication Date
AR029139A1 true AR029139A1 (es) 2003-06-04

Family

ID=24424265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102841A AR029139A1 (es) 2000-06-28 2001-06-14 Interleuquina 2 estabilizada

Country Status (24)

Country Link
US (1) US6689353B1 (es)
EP (1) EP1370280B1 (es)
JP (3) JP5522878B2 (es)
KR (1) KR100799402B1 (es)
CN (1) CN1523997B (es)
AR (1) AR029139A1 (es)
AU (1) AU2001273063A1 (es)
BR (1) BR0112101B1 (es)
CA (1) CA2413334C (es)
CO (1) CO5290308A1 (es)
CU (1) CU23536A3 (es)
DE (1) DE60142412D1 (es)
DO (1) DOP2001000197A (es)
EC (1) ECSP014106A (es)
ES (1) ES2344729T3 (es)
HN (1) HN2001000139A (es)
IL (2) IL153587A0 (es)
MX (1) MXPA03000046A (es)
MY (1) MY128629A (es)
PE (1) PE20020127A1 (es)
SV (1) SV2002000512A (es)
TW (1) TWI235063B (es)
UY (1) UY26805A1 (es)
WO (1) WO2002000243A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8531276B2 (en) * 2000-03-15 2013-09-10 Logitech Europe S.A. State-based remote control system
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
MXPA06011580A (es) 2004-04-08 2007-05-04 Biomatrica Inc Integracion de almacenamiento de muestras y administracion de muestras para las ciencias de la vida.
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
JP2008531722A (ja) 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション 構造的に安定なコンジュゲート分子を含む組成物
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2009012964A (es) 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
EP2430195B1 (en) * 2009-05-11 2019-01-23 Biomatrica, INC. Compositions and methods for biological sample storage
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
MX388465B (es) 2010-11-12 2025-03-20 Nektar Therapeutics Conjugados de un resto de interleucina-2 y un polímero.
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2819246C (en) * 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
CN103063829B (zh) * 2012-12-21 2015-01-14 杭州茂天赛科技有限公司 一种冻存液
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
ES3037826T3 (en) 2015-12-08 2025-10-07 Biomatrica Inc Reduction of erythrocyte sedimentation rate
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3773680A1 (en) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Il-2 conjugates
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230107598A (ko) * 2020-11-13 2023-07-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인간 인터루킨 2 변이체 또는 이의 유도체를 포함하는 약학적 조성물 및 이의 용도
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215631A (ja) * 1984-04-09 1985-10-29 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
JPH0229016A (ja) * 1989-06-09 1990-01-31 Alpine Electron Inc イコライザ装置
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6509023B1 (en) * 1997-07-31 2003-01-21 Rhodia Chimie Cosmetic composition comprising a functionalized polyorganosiloxane
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2

Also Published As

Publication number Publication date
DOP2001000197A (es) 2003-01-15
JP2004532791A (ja) 2004-10-28
ECSP014106A (es) 2002-02-25
JP2015007114A (ja) 2015-01-15
KR20030016312A (ko) 2003-02-26
WO2002000243A3 (en) 2003-10-02
MXPA03000046A (es) 2003-06-19
CO5290308A1 (es) 2003-06-27
CA2413334C (en) 2011-03-08
CN1523997A (zh) 2004-08-25
KR100799402B1 (ko) 2008-01-30
PE20020127A1 (es) 2002-04-27
UY26805A1 (es) 2002-01-31
IL153587A (en) 2007-12-03
JP2012211166A (ja) 2012-11-01
ES2344729T3 (es) 2010-09-06
JP5522878B2 (ja) 2014-06-18
AU2001273063A1 (en) 2002-01-08
BR0112101A (pt) 2004-07-06
EP1370280B1 (en) 2010-06-16
EP1370280A2 (en) 2003-12-17
CA2413334A1 (en) 2002-01-03
US6689353B1 (en) 2004-02-10
SV2002000512A (es) 2002-07-03
DE60142412D1 (de) 2010-07-29
WO2002000243A2 (en) 2002-01-03
MY128629A (en) 2007-02-28
HN2001000139A (es) 2003-12-11
CN1523997B (zh) 2010-09-01
BR0112101B1 (pt) 2017-11-14
JP5989728B2 (ja) 2016-09-07
TWI235063B (en) 2005-07-01
CU23536A3 (es) 2010-06-17
IL153587A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
AR029139A1 (es) Interleuquina 2 estabilizada
IT1240314B (it) Formulazioni acquose stabilizzate di piccoli peptidi.
CY1113353T1 (el) Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος
ATE230277T1 (de) Stabilisierte antikörperformulierung
LU91342I2 (fr) Byetta-exénatide
HRP20041152B1 (hr) Farmaceutske formulacije
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
IS7043A (is) Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu
DE69522562D1 (de) Eine glucagon enthaltende pharmazeutische zubereitung
TR200002812T2 (tr) Efervesan formülasyonları.
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
DE69723278D1 (de) Pharmazeutische ampulle
CY1105465T1 (el) Μορφη δοσολογιας πepιλαμβανουσα υγρο σκευασμα
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
DE50003454D1 (de) Proteinenthaltende pharmazeutische zubereitung
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
AR037131A1 (es) Formulaciones de jarabe de ribavirina
DK0797997T3 (da) Anvendelse af peptidiske bradykinin-antagonister til fremstilling af lægemidler
ES2038546B1 (es) Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral.
FI912461A7 (fi) Pienten peptidien stabiloituja vesipitoisia formuloita
DK0981332T3 (da) Farmaceutisk præparat omfattende frysetörrede liposomer, som indkapsler et aktivt stof, der er stærkt uoplöseligt i vand samt fremgangsmåde til fremstilling af præparatet
TH43906B (th) อินเทอร์ลูคิน 2 ที่ถูกทำให้เสถียรแล้ว

Legal Events

Date Code Title Description
FG Grant, registration